Soon enough, Jørgen Jensen will have his hands full when sitting at the end of the table in Ambu's board room, as he was nominated as Lars Rasmussen's replacement on Friday.
Aside from the new chair position at Ambu, 52-year-old Jensen is also the chair of window company Velux, 3Shape and the public-private collaboration Healthcare Denmark, which markets the Danish health industry abroad.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.